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and Veronica M. Vieira, DSc
OBJECTIVE: To validate the observed/expected ratio for
adherence to ovarian cancer treatment guidelines as
a risk-adjusted measure of hospital quality care, and to
identify patient characteristics associated with disparities
in access to high-performing hospitals.
METHODS: This was a retrospective population-based
study of stage I–IV invasive epithelial ovarian cancer reported
to the California Cancer Registry between 1996 and 2014. A
fit logistic regression model, which was risk-adjusted for
patient and disease characteristics, was used to calculate
the observed/expected ratio for each hospital, stratified by
hospital annual case volume. A Cox proportional hazards
model was used for survival analyses, and a multivariable
logistic regression model was used to identify independent
predictors of access to high-performing hospitals.
RESULTS: The study population included 30,051 patients
who were treated at 426 hospitals: low observed/expected
ratio (n5304) 23.5% of cases; intermediate observed/ex-
pected ratio (n592) 57.8% of cases; and high observed/
expected ratio (n530) 18.7% of cases. Hospitals with high
observed/expected ratios were significantly more likely to
deliver guideline-adherent care (53.3%), compared with
hospitals with intermediate (37.8%) and low (27.5%)
observed/expected ratios (P,.001). Median disease-
specific survival time ranged from 73.0 months for hospitals
with high observed/expected ratios to 48.1 months for hos-
pitals with low observed/expected ratios (P,.001). Treat-
ment at a hospital with a high observed/expected ratio
was an independent predictor of superior survival com-
pared with hospitals with intermediate (hazard ratio [HR]
1.06, 95% CI 1.01–1.11, P,.05) and low (HR 1.10, 95% CI
1.04–1.16, P,.001) observed/expected ratios. Being of His-
panic ethnicity (odds ratio [OR] 0.85, 95% CI 0.78–0.93,
P,.001, compared with white), having Medicare insurance
(OR 0.74, 95% CI 0.68–0.81 P,.001, compared with man-
aged care), having a Charlson Comorbidity Index score of 2
or greater (OR 0.91, 95% CI 0.83–0.99, P,.05), and being of
lower socioeconomic status (lowest quintile OR 0.41, 95%
CI 0.36–0.46, P,.001, compared with highest quintile) were
independent negative predictors of access to a hospital
with a high observed/expected ratio.
CONCLUSION: Ovarian cancer care at a hospital with
a high observed/expected ratio is an independent pre-
dictor of improved survival. Barriers to high-performing
hospitals disproportionately affect patients according to
sociodemographic characteristics. Triage of patients with
suspected ovarian cancer according to a performance-
based observed/expected ratio hospital classification is
a potential mechanism for expanded access to expert
care.
(Obstet Gynecol 2020;135:328–39)
DOI: 10.1097/AOG.0000000000003665
The mortality rate for ovarian cancer has decreasedby 33% over the past 40 years owing to a modest
decrease in incidence coupled with substantial im-
provements in treatment.1,2 Treatment advances are
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reflected in the National Comprehensive Cancer Net-
work’s treatment guidelines, which are the accepted
standard for quality ovarian cancer care.3–9 Unfortu-
nately, a majority of patients with ovarian cancer do
not receive the recommended care, and race, poverty
level, and insurance status have been identified as
independent predictors of an increased likelihood of
treatment that deviates from standard guide-
lines.3,4,10–13
For ovarian cancer, eliminating sociodemo-
graphic disparities and improving outcomes for all
segments of the population hinges on universal access
to expert care.14–17 Accordingly, a definition of
hospital-based expert ovarian cancer care that is both
valid and practical is a necessary first step. Although
high-volume hospital care (more than 20 cases per
year) correlates with adherence to National Compre-
hensive Cancer Network treatment guidelines, crude
case volume alone is an imprecise measure of quality
care, and there are relatively few centers with the
required caseload.9,18 Recently, Wright et al9 studied
100,725 patients and 1,268 hospitals from the
National Cancer Database, and reported that increas-
ing annual case volume and adherence to quality met-
rics were associated with improved survival outcome.
Our group previously reported a more precise
hospital-based quality metric for ovarian cancer care—
the observed/expected ratio for adherence to National
Comprehensive Cancer Network guidelines—combin-
ing structural, process, and outcome measures with risk
adjustment for patient population characteristics.8,19,20
There are multiple patient- and disease-related factors
that preclude 100% adherence to ovarian cancer treat-
ment guidelines. The observed/expected ratio instru-
ment accounts for differences in case-mix complexity
among hospitals and provides a measure of guideline
adherence that is adjusted for these confounding fac-
tors. The objectives of the current study were to 1)
validate the utility of the observed/expected ratio
methodology using an expanded California Cancer
Registry data set with risk adjustment for patient and
disease characteristics and 2) investigate sociodemo-
graphic characteristics associated with disparities in
access to high-performing hospitals.
METHODS
This was a retrospective population-based study of
invasive epithelial ovarian cancer reported to Califor-
nia Cancer Registry between January 1, 1996, and
December 31, 2014, with follow-up through 2016 and
record linkage to the California Office of Statewide
Health Planning and Development database. The
study received exempt status by the Institutional
Review Board of the University of California, Irvine
(UCI 14-66/HS# 2014-1476). The California Cancer
Registry is California’s statewide population-based
cancer surveillance system that has collected informa-
tion about tumor characteristics, patient characteris-
tics, and treatment for all cancers diagnosed in
California since 1988.21 Standardized data collection
and quality control procedures have been in place
since that time. Case reporting is estimated to be
99% for the entire state of California, with follow-up
completion rates exceeding 95%.22 International Clas-
sification of Disease Codes for Oncology based on
World Health Organization criteria were used for
tumor location and histology. Cases were identified
using the Surveillance, Epidemiology, and End Re-
sults ovary primary site code (C569).
Cases included patients who were aged 18 years
or older and were diagnosed with a first or only
invasive epithelial ovarian cancer from 1996 to 2014.
Those with incomplete clinical information, nonepi-
thelial histologic subtypes, missing International Clas-
sification of Disease Codes for Oncology morphology
code, or data extracted from autopsy or death
certificate only were excluded (Fig. 1). A total of
30,051 patients were included in the final sample for
analysis. Age at diagnosis was treated either as a con-
tinuous or a categorical variable. Other patient socio-
demographic characteristics included race–ethnicity
and insurance type. Socioeconomic status was classi-
fied into quintiles based on the Yost or Yang score.
The Yost score was used for patients diagnosed before
2006 and is a composite index of socioeconomic sta-
tus based on a principal component analysis of block
group level census variables (eg, education, income
and occupation).23 The Yang scale is a similar index
based on American Community Survey variables at
the block group level (for patients who were diag-
nosed after 2006).24 The Deyo adaptation of the
Charlson Comorbidity Index was used a measure of
patient comorbidity.25 Comorbidity scores were cal-
culated for each patient using diagnosis codes
included in California Office of Statewide Health
Planning and Development hospital discharge data
before the cancer diagnosis. Charlson Comorbidity
Index score was categorized into four groups: 0, 1, 2
or greater, or unknown. Tumor characteristic
included stage, tumor grade, and histology. Hospital
volume was calculated based on the average annual
number of ovarian cancer cases admitted in that
hospital and included both surgical and nonsurgical
cases. Hospitals with 20 or more cases per year were
classified as high-volume; hospitals with fewer than 20
cases per year were considered low-volume.
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Adherence to treatment guidelines for ovarian
cancer was based on National Comprehensive Cancer
Network recommendations for surgery and chemo-
therapy according to the time period of diagnosis
(1996–2014).26–33 Surgical treatment for stages I–IIIB
was considered adherent to National Comprehensive
Cancer Network guidelines if it included a minimum
of oophorectomy, pelvic or para-aortic lymph node
biopsy, and omentectomy. A minimum of oophorec-
tomy and omentectomy was considered adherent sur-
gical care for International Federation of Gynecology
and Obstetrics stages IIIC–IV disease. For patients
with stages IA–IB, grade 1–2 disease, no adjuvant
treatment was considered adherent to National Com-
prehensive Cancer Network guidelines. Administra-
tion of multi-agent chemotherapy was considered
adherent care for patients with stages IC–IV or grade
3 diseases, and surgery must have preceded chemo-
therapy for those with stages I–IIIB. For stages IIIC–
IV either initial surgery or chemotherapy was charac-
terized as appropriate care. Dichotomous variables,
adherence or nonadherence, were created for adher-
ence to surgical guidelines, chemotherapy guidelines,
and the overall treatment plan (both surgery and
chemotherapy).
Two steps were carried out to calculate the
hospital-based observed/expected ratio for adherence
to treatment guidelines, which were risk-adjusted for
patient and tumor characteristics. Univariate analyses
were conducted first to examine the relation between
each predictor variable and overall treatment adher-
ence using x2 test for categorical variable and t test for
continuous variable. Model selection was based on
univariate analyses augmented by clinical knowledge.
Predictors in the final logistic model for overall adher-
ence included only those patient and disease charac-
teristics relevant to treatment received: age at
diagnosis, year of diagnosis, Charlson Comorbidity
Index score, tumor stage, grade, histology, and size.
The c-statistic was used to measure the predictive
accuracy of the model (c-statistic50.79), and
Hosmer-Lemeshow test was used to test the calibra-
tion of the model and showed that the final logistic
model provided adequate fit. In the second step, the
final multivariate logistic model was used to estimate
the probability of adherence to National Comprehen-
sive Cancer Network overall treatment plan for each
patient. Expected adherence for each hospital was cal-
culated by summing the probabilities of adherence for
all patients who were treated in that center. Observed
adherence for each hospital was calculated as the
number of patients who received adherent care in
the center. A high observed/expected ratio indicated
that the hospital had a higher rate of adherence to the
guidelines than would be expected according to its
patient mix. Centers with very low case volume
tended to have too few cases to calculate a stable
observed/expected ratio, and sensitivity analysis re-
vealed that hospitals with five or more cases had a sta-
ble SD of observed/expected ratio. Thus, centers were
grouped according to observed/expected ratio and
case volume into three categories: low observed/ex-
pected ratio (lowest quartile of observed/expected
ratio or annual case volume less than 5), intermediate
observed/expected ratio (middle two quartiles of
observed/expected ratio and annual case volume 5
or more), and high observed/expected ratio (highest
quartile of observed/expected ratio and annual case
volume of 5 or more).
Cause of death was recorded according to Inter-
national Classification of Diseases criteria in effect at
the time of death.34 The last date of follow-up was
either the date of death or the date of last contact.
Ovarian cancer-specific mortality was defined as
death caused by ovarian cancer alone, and patients
who died from other causes were treated as censored
cases at the time of the event.
Descriptive statistics for demographic and clinical
characteristics were analyzed with x2 test for categor-
ical variables. The first main outcome variable
was disease-specific survival. Survival analysis was
Fig. 1. STROBE (Strengthening the Reporting of Observa-
tional Studies in Epidemiology) exclusion flowchart.
Bristow. Risk-Adjusted Model for Ovarian Cancer Care. Obstet
Gynecol 2020.
330 Bristow et al Risk-Adjusted Model for Ovarian Cancer Care OBSTETRICS & GYNECOLOGY
performed using the Kaplan-Meier estimate of sur-
vival probability and log-rank test. After verifying
the proportionality assumption, a Cox proportional
hazards model was fitted to evaluate the independent
effect on survival of each predictor. Possible interac-
tion terms of main effects were tested, and statistically
insignificant factors were removed from the final
model using stepwise selection. Adjusted hazard ratios
(HRs) and 95% CIs were generated. The second main
outcome variable was access to hospitals with high
observed/expected ratios. Multivariable logistic
regression analysis was performed to estimate the
probability of receiving treatment at a hospital with
a high observed/expected ratio. All statistical analysis
was performed on SAS 9.4.
RESULTS
For the final study population of 30,051 patients with
invasive epithelial ovarian cancer, sociodemographic
variables, tumor-related characteristics, and hospital
classification, stratified by National Comprehensive
Cancer Network guideline adherence, are shown in
Table 1. For all cases, 38.3% were adherent to
National Comprehensive Cancer Network treatment
guidelines, with adherence to the surgical and chemo-
therapy components in 54.0% and 62.7% of all cases,
respectively.
A total of 426 hospitals were identified as pro-
viding ovarian cancer care during the study period;
the proportional distributions of hospitals and patients
according to observed/expected ratio classification
and average annual case volume are shown in Table 2.
The 304 hospitals with low observed/expected ratios
represented 71.4% of treating facilities and accounted
for 7,068 cases (23.5%); the 92 hospitals with interme-
diate observed/expected ratios represented 21.6% of
all facilities and treated 57.8% of patients. There were
30 hospitals with high observed/expected ratios (7%
of all facilities), which accounted for 18.7% of cases.
Hospitals with high observed/expected ratios were
significantly more likely to deliver National Compre-
hensive Cancer Network guideline–adherent care
(53.3%) compared with hospitals with intermediate
(37.8%) and low (27.5%) observed/expected ratios
(P,.001) (Table 1). By comparison, classification ac-
cording to annual case volume alone identified 14
hospitals that met the high-volume criterion (20 or
more cases per year).15,35 Ovarian cancer care was
adherent to National Comprehensive Cancer Net-
work guidelines for 48.9% of patients treated at
high-volume hospitals, compared with 35.4% of those
treated at low-volume hospitals (P,.001).
Univariate survival analysis revealed that the
median disease-specific survival time was different
across hospital observed/expected ratio categories:
48.1 months at hospitals with low observed/expected
ratios (95% CI 44.8–50.8 months); 62.4 months at
hospitals with intermediate observed/expected ratios
(95% CI 60.1–65.5 months); and 73.0 months at hos-
pitals with high observed/expected ratios (95% CI
68.6–79.3 months), P,.001 (Fig. 2). Multivariate sur-
vival analysis revealed the expected survival effects
of tumor grade, stage, and histologic subtype
(Table 3). Being of non-Hispanic black race, not
being married, having a Charlson Comorbidity
Index score of 1 or greater, having Medicaid insur-
ance or no insurance, and being of a lower socioeco-
nomic status were associated with a worse survival
outcome. After controlling for other variables, care
at a hospital with a high observed/expected ratio was
significantly and independently associated with supe-
rior disease-specific survival compared with hospitals
with intermediate observed/expected ratios (HR
1.06, 95% CI 1.01–1.11, P5.022) and those with
low observed/expected ratios (HR 1.10, 95% CI
1.04–1.16, P,.001).
The geographic distribution of the 426 hospitals
treating patients with ovarian cancer, classified
according to observed/expected ratio status and high
annual case volume, is shown in Figure 3. The north-
ernmost regions and mid-section of the state were
predominantly serviced by hospitals with low and
intermediate observed/expected ratios. The 30 hos-
pitals with high observed/expected ratios and 14
high-volume centers were largely concentrated
around population-dense areas in Northern and
Southern California. A cross-tabulation by hospital
observed/expected ratio classification and case vol-
ume revealed that only 2 of the 30 hospitals with
high observed/expected ratios also had high average
annual case volume; both were located in Northern
California (Table 4 and Fig. 3, top inset). In other
words, 93.3% of hospitals with high observed/ex-
pected ratios were not high-volume, and only
14.3% of hospitals with high annual case volumes
met the performance-based metric of having a high
observed/expected ratio.
Multivariable analysis of sociodemographic and
clinical characteristics and treatment at a hospital with
a high observed/expected ratio revealed a small but
statistically significant positive effect for increasing
year of diagnosis (Table 5). Among clinical character-
istics, patients with a Charlson Comorbidity Index
score of 2 or greater were less likely to receive care
at a hospital with a high observed/expected ratio; care
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Table 1. Study Population Characteristics According to Sociodemographic Variables, Tumor
Characteristics, Hospital Classification, and Treatment Guideline Adherence
Characteristic
Total,
n530,051 (100)
Treatment Plan
Adherent,
n511,501 (38.3)
Surgery
Adherent,
n516,224 (54.0)
Chemotherapy
Adherent,
n518,836 (62.7)
Patient demographics
Age at diagnosis (y)
18–44 4,233 (14.1) 1,519 (35.9) 2,122 (50.1) 2,723 (64.3)
45–54 6,475 (21.6) 2,827 (43.7) 3,837 (59.3) 4,429 (68.4)
55–64 7,273 (24.2) 3,384 (46.5) 4,493 (61.8) 5,113 (70.3)
65 or older 12,070 (40.2) 3,771 (31.2) 5,772 (47.8) 6,571 (54.4)
Year of diagnosis period
1996–1999 5,262 (17.5) 2,020 (38.4) 2,692 (51.2) 3,522 (66.9)
2000–2004 7,489 (24.9) 2,852 (38.1) 4,169 (55.7) 4,572 (61.0)
2005–2009 8,311 (27.7) 3,135 (37.7) 4,486 (54.0) 5,045 (60.7)
2010–2014 8,989 (29.9) 3,494 (38.9) 4,877 (54.3) 5,697 (63.4)
Race
Non-Hispanic white 19,059 (63.4) 7,592 (39.8) 10,644 (55.8) 12,001 (63.0)
Non-Hispanic black 1,424 (4.7) 425 (29.8) 618 (43.4) 813 (57.1)
Hispanic 5,785 (19.3) 2,034 (35.2) 2,905 (50.2) 3,604 (62.3)
Asian or Pacific Islander 3,582 (11.9) 1,385 (38.7) 1,955 (54.6) 2,299 (64.2)
Native American or unknown 201 (0.7) 65 (32.3) 102 (50.7) 119 (59.2)
Insurance
Managed care 14,229 (47.4) 5,862 (41.2) 8,130 (57.1) 9,241 (64.9)
Medicare 7,712 (25.7) 2,460 (31.9) 3,718 (48.2) 4,290 (55.6)
Medicaid 2,751 (9.2) 1,014 (36.9) 1,367 (49.7) 1,820 (66.2)
Other insurance 3,854 (12.8) 1,649 (42.8) 2,287 (59.3) 2,564 (66.5)
Not insured 897 (3.0) 276 (30.8) 378 (42.1) 544 (60.6)
Unknown 608 (2.0) 240 (39.5) 344 (56.6) 377 (62.0)
SES category
Lowest 4,068 (13.5) 1,235 (30.4) 1,863 (45.8) 2,342 (57.6)
Lower-middle 5,477 (18.2) 1,891 (34.5) 2,735 (49.9) 3,290 (60.1)
Middle 6,367 (21.2) 2,395 (37.6) 3,403 (53.4) 3,978 (62.5)
Higher-middle 6,901 (23.0) 2,782 (40.3) 3,870 (56.1) 4,410 (63.9)
Highest 7,238 (24.1) 3,198 (44.2) 4,353 (60.1) 4,816 (66.5)
Marital status
Single or unknown 14,806 (49.3) 5,076 (34.3) 7,416 (50.1) 8,636 (58.3)
Married 15,245 (50.7) 6,425 (42.1) 8,808 (57.8) 10,200 (66.9)
CCI score
0 14,309 (47.6) 5,971 (41.7) 8,288 (57.9) 9,426 (65.9)
1 6,847 (22.8) 2,759 (40.3) 3,868 (56.5) 4,390 (64.1)
2 or greater 6,768 (22.5) 2,091 (30.9) 3,111 (46.0) 3,762 (55.6)
Unknown 2,127 (7.1) 680 (32.0) 957 (45.0) 1,258 (59.1)
Tumor characteristics
Grade (differentiation)
I (well differentiated) 2,392 (8.0) 789 (33.0) 1,129 (47.2) 1,712 (71.6)
II (moderately well differentiated) 4,383 (14.6) 1,729 (39.4) 2,578 (58.8) 2,868 (65.4)
III (poorly differentiated) 10,115 (33.7) 4,927 (48.7) 6,756 (66.8) 7,024 (69.4)
IV (undifferentiated or anaplastic) 4,218 (14.0) 2,305 (54.6) 3,043 (72.1) 3,075 (72.9)
Grade and differentiation not stated 8,943 (29.8) 1,751 (19.6) 2,718 (30.4) 4,157 (46.5)
Stage
I 7,287 (24.3) 1,733 (23.8) 2,928 (40.2) 4,026 (55.2)
II 2,510 (8.4) 734 (29.2) 1,151 (45.9) 1,510 (60.2)
III 11,348 (37.8) 5,986 (52.7) 8,082 (71.2) 7,985 (70.4)
IV 8,906 (29.6) 3,048 (34.2) 4,063 (45.6) 5,315 (59.7)
Size (cm)
Less than 5 3,762 (12.5) 1,521 (40.4) 2,073 (55.1) 2,468 (65.6)
5–10 5,926 (19.7) 2,613 (44.1) 3,614 (61.0) 3,949 (66.6)
More than 10 9,406 (31.3) 3,778 (40.2) 5,596 (59.5) 5,958 (63.3)
Unknown 10,957 (36.5) 3,589 (32.8) 4,941 (45.1) 6,461 (59.0)
(continued )
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at a hospital with a high observed/expected ratio was
more likely for patients with stage III disease and
tumor size larger than 10 cm. Among sociodemo-
graphic characteristics, being of Hispanic ethnicity
(odds ratio [OR] 0.85, 95% CI 0.78–0.93, P,.001,
compared with white) and having Medicare insurance
(OR 0.74, 95% CI 0.68–0.81, P,.001, compared with
managed care) were independent negative predictors
of access to a hospital with a high observed/expected
ratio. In contrast, being of Asian or Pacific Islander
race (OR 1.21, 95% CI 1.11 1.33, P,.001, compared
with white) and having Medicaid insurance (OR 1.19,
95% CI 1.07–1.33, P5.002, compared with managed
care) or no insurance (OR 1.41, 95% CI 1.20–1.66,
P,.001, compared with managed care) were predic-
tive of a higher likelihood of treatment at a hospital
with a high observed/expected ratio. Notably, socio-
economic status was independently associated with
the likelihood of treatment at a hospital with a high
observed/expected ratio, decreasing in a linear fash-
ion from the highest socioeconomic status quintile
(OR 1.00) to the lowest socioeconomic status quintile
(OR 0.41, 95% CI 0.36–0.46, P,.001). In other
words, patients in the highest socioeconomic status
quintile were almost 2.5 times more likely to access
a hospital with a high observed/expected ratio than
their counterparts in the lowest socioeconomic status
quintile.
Table 1. Study Population Characteristics According to Sociodemographic Variables, Tumor
Characteristics, Hospital Classification, and Treatment Guideline Adherence (continued )
Characteristic
Total,
n530,051 (100)
Treatment Plan
Adherent,
n511,501 (38.3)
Surgery
Adherent,
n516,224 (54.0)
Chemotherapy
Adherent,
n518,836 (62.7)
Histology
Serous 12,943 (43.1) 6,618 (51.1) 8,831 (68.2) 9,128 (70.5)
Mucinous 1,915 (6.4) 548 (28.6) 876 (45.7) 1,115 (58.2)
Endometrioid 3,334 (11.1) 1,184 (35.5) 1,828 (54.8) 2,145 (64.3)
Clear cell 1,837 (6.1) 711 (38.7) 1,069 (58.2) 1,187 (64.6)
Adenocarcinoma, NOS 3,202 (10.7) 555 (17.3) 762 (23.8) 1,748 (54.6)
Others 6,820 (22.7) 1,885 (27.6) 2,858 (41.9) 3,513 (51.5)
Health care provider characteristics
Annual hospital volume
Low (less than 20) 23,709 (78.9) 8,399 (35.4) 12,224 (51.6) 14,316 (60.4)
High (20 or more) 6,342 (21.1) 3,102 (48.9) 4,000 (63.1) 4,520 (71.3)
O/E ratio category
Low or fewer than 5 cases/y 7,068 (23.5) 1,943 (27.5) 3,181 (45.0) 3,684 (52.1)
Intermediate 17,371 (57.8) 6,568 (37.8) 9,383 (54.0) 11,007 (63.4)
High 5,612 (18.7) 2,990 (53.3) 3,660 (65.2) 4,145 (73.9)
SES, socioeconomic status; CCI, Charlson Comorbidity Index; NOS, not otherwise specified; O/E, observed/expected.
Data are n (%).
All associations between characteristics and adherence categories were statistically significant with P,.001 by the x2 test.
Table 2. Distribution of 426 Ovarian Cancer–Treating Hospitals According to Average Annual Case Volume
and Observed/Expected Ratio* Classification
Hospitals Cases O/E Ratio Score
Hospital O/E ratio classification
1 (lowest quartile or fewer than 5 cases) 304 (71.4) 7,068 (23.5) 0.8660.62
2 (intermediate) 92 (21.6) 17,371 (57.8) 0.9460.15
3 (highest quartile) 30 (7.0) 5,612 (18.7) 1.3460.11
Hospital volume (cases/y)
Fewer than 2 159 (37.3) 1,116 (3.7) 0.8960.78
2–4.99 134 (31.5) 4,526 (15.1) 0.8560.36
5–9.99 73 (17.1) 7,811 (26.0) 0.9760.25
10–19.99 46 (10.8) 10,256 (34.1) 1.0560.27
20 or more 14 (3.3) 6,342 (21.1) 0.9860.16
* Observed/expected ratio for adherence to National Comprehensive Cancer Network guidelines.
Data are n (%) or mean6SD.
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DISCUSSION
A significant proportion of patients with ovarian cancer
in the United States do not receive the recommended
standard of care for initial treatment, although defini-
tions and methodologies differ across populations
and study designs. In population-based studies, the
rate of adherence to National Comprehensive Cancer
Network treatment guidelines has been reported as
30.2–65.9%, and in single-institution studies it ranges
from 26.7% to 85.4%.3–7,10,18,35 The reasons behind
this trend are multifactorial and include medical co-
morbidities precluding surgery or chemotherapy, lim-
ited availability of or access to high-volume specialty
health care providers, and barriers to care associated
with sociodemographic and geographic characteris-
tics.4–6,10,35–38 Although development of novel thera-
peutic agents and innovative treatment strategies for
ovarian cancer offer the potential for improved sur-
vival, the most basic mechanism for immediately
improving outcomes is to increase adherence to
accepted treatment guidelines.
The current data suggest that the observed/
expected ratio methodology offers a means of
distinguishing high-performing ovarian cancer hos-
pitals with improved outcomes while expanding the
number of designated expert centers beyond the
traditional, and less precise, structural measure of
average annual case volume. In California, adoption
of the performance-based observed/expected ratio
methodology for designating preferred hospitals for
ovarian cancer care would more than double the
number of potential referral facilities associated with
superior outcomes. Surprisingly, the current data
indicate minimal overlap between hospitals with
high observed/expected ratios and high-volume
hospitals. Only 2 of the 14 high-volume hospitals
also had high observed/expected ratios; conversely,
just 2 of the 30 hospitals with high observed/
expected ratios were also high-volume.
Admittedly, hospitals with high observed/ex-
pected ratios treated a modest proportion of all
patients with ovarian cancer, so that redistribution of
patients with ovarian cancer according a performance-
based metric still presents the challenge of achieving
widespread access to designated institutions. In the
current report, 93% of hospitals that treated patients
with ovarian cancer did not have high observed/
expected ratios. Substantially increasing the rate of
adherence to guidelines or annual case volume for
these 396 facilities is likely impractical. A more
workable approach may be to concentrate care in
the 30 hospitals with demonstrable high performance
that uses a preferential triage strategy. This approach
has been successfully adopted for a number of high-
risk procedures and treatments.39 An increasing body
of evidence now supports concentration of ovarian
cancer care to improve adherence to treatment guide-
lines, surgical outcomes, survival, and cost-effective-
ness.40,41 For example, Dahm-Kähler et al42 reported
the effect of centralization of ovarian cancer care in
Sweden and found an improved rate of complete cy-
toreductive surgery, a decrease in the time interval
from surgery to chemotherapy, and a 50% improve-
ment in 3-year survival. These data, combined with an
increasing focus being placed on patient safety and
quality improvement, suggest that a coordinated effort
from health care policy administrators, professional
societies, advocacy organizations, and payers to con-
centrate ovarian cancer care in high-performing cen-
ters is warranted.
Fig. 2. Ovarian cancer-specific
survival by hospital observed/
expected (O/E) ratio category.
Bristow. Risk-Adjusted Model for
Ovarian Cancer Care. Obstet
Gynecol 2020.
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Table 3. Unadjusted and Adjusted Hazard Ratios for Disease-Specific Survival for Sociodemographic
Variables, Tumor Characteristics, and Hospital Classification
Characteristic Unadjusted HR (95% CI) Adjusted HR (95% CI)
Patient demographics
Race
Non-Hispanic white 1.00 1.00
Non-Hispanic black 1.59 (1.47–1.71)* 1.28 (1.18–1.38)*
Hispanic 1.10 (1.05–1.15)* 0.97 (0.92–1.02)
Asian or Pacific Islander 0.92 (0.87–0.98)† 0.99 (0.93–1.05)
Native American or unknown 0.88 (0.70–1.11) 0.86 (0.68–1.10)
Insurance
Managed care 1.00 1.00
Medicare 1.05 (1.01–1.10)‡ 0.96 (0.92–1.01)
Medicaid 1.46 (1.37–1.55)* 1.14 (1.06–1.22)*
Other insurance 0.95 (0.90–1.01) 0.96 (0.90–1.02)
Not insured 1.41 (1.27–1.56)* 1.23 (1.10–1.38)*
Unknown 1.19 (1.06–1.35)† 0.94 (0.83–1.07)
SES category
Highest 1.00 1.00
Higher-middle 1.08 (1.03–1.13)† 1.06 (1.004–1.11)‡
Middle 1.13 (1.07–1.18)* 1.10 (1.04–1.16)*
Lower-middle 1.30 (1.24–1.37)* 1.20 (1.14–1.27)*
Lowest 1.33 (1.25–1.41)* 1.18 (1.11–1.26)*
Marital status
Single or unknown 1.00 1.00
Married 0.88 (0.85–0.91)* 0.92 (0.89–0.96)*
CCI score
0 1.00 1.00
1 1.29 (1.24–1.35)* 1.16 (1.11–1.21)*
2 or greater 1.21 (1.16–1.26)* 1.06 (1.01–1.11)‡
Unknown 1.19 (1.10–1.29)* 1.02 (0.93–1.11)
Tumor characteristics
Grade (differentiation)
I (well differentiated) 1.00 1.00
II (moderately well differentiated) 2.41 (2.15–2.70)* 1.64 (1.46–1.84)*
III (poorly differentiated) 3.95 (3.55–4.39)* 1.79 (1.60–2.00)*
IV (undifferentiated or anaplastic) 3.86 (3.45–4.31)* 1.79 (1.59–2.02)*
Grade and differentiation not stated 5.18 (4.65–5.76)* 2.24 (2.00–2.52)*
Stage
I 1.00 1.00
II 2.44 (2.21–2.70)* 2.49 (2.25–2.76)*
III 6.68 (6.21–7.18)* 6.57 (6.08–7.11)*
IV 12.64 (11.73–13.62)* 10.70 (9.87–11.60)*
Size (cm)
Less than 5 1.00 1.00
5–10 1.08 (1.01–1.14)‡ 1.01 (0.95–1.08)
More than10 0.86 (0.81–0.92)* 0.95 (0.89–1.01)
Unknown 1.61 (1.52–1.70)* 1.16 (1.10–1.23)*
Histology
Serous 1.00 1.00
Mucinous 0.51 (0.47–0.56)* 1.40 (1.26–1.54)*
Endometrioid 0.36 (0.34–0.39)* 0.82 (0.75–0.88)*
Clear cell 0.57 (0.52–0.62)* 1.27 (1.16–1.39)*
Adenocarcinoma, NOS 1.92 (1.82–2.02)* 1.43 (1.35–1.51)*
Others 1.11 (1.06–1.16)* 1.31 (1.25–1.37)*
Hospital O/E ratio category
Low or fewer than 5 cases/y 1.23 (1.17–1.29)* 1.10 (1.04–1.16)*
Intermediate 1.06 (1.01–1.11)‡ 1.06 (1.01–1.11)‡
High 1.00 1.00
HR, hazard ratio; SES, socioeconomic status; CCI, Charlson Comorbidity Index; NOS, not otherwise specified; O/E, observed/expected.
Both unadjusted and adjusted hazard ratios are from Cox models and included age at diagnosis in years and year of ovarian cancer diagnosis
as strata.
* P,.001.
† P,.01.
‡ P,.05.
VOL. 135, NO. 2, FEBRUARY 2020 Bristow et al Risk-Adjusted Model for Ovarian Cancer Care 335
Improving the health of all sociodemographic
groups is a national priority; however, the National
Healthcare Quality and Disparities Report indicates
that disparities in access to care across race–ethnicity
and socioeconomic status have remained largely
unchanged in recent years.43 The current data show
that barriers to high-performing facilities dispropor-
tionately affect patients with: Hispanic ethnicity,
Medicare insurance, a Charlson Comorbidity Index
score of 2 or greater, and a lower socioeconomic sta-
tus. The strongest effect was seen for socioeconomic
status, where patients in the highest socioeconomic
status quintile were almost 2.5 times more likely to
access a hospital with a high observed/expected ratio
compared with those in the lowest socioeconomic sta-
tus quintile. Sociodemographic disparities in ovarian
cancer survival are thought to be largely attributable
to unequal access to care and administration of non-
standard treatment regimens, primarily as a conse-
quence of lower socioeconomic status, community
disadvantage, and safety net insurance or lack of cov-
erage altogether among disadvantaged and minority
populations.13,36,44 This premise is supported by data
indicating that, when patients receive comparable
treatment, disparities in ovarian cancer survival ac-
cording to race–ethnicity and socioeconomic status
are largely mitigated.10,45–47 If the fundamental goal is
health care equity, all segments of the population
should not only have equal access to high-quality care,
but resources must be directed toward remediating
the underlying barriers to actually obtaining such care
for underserved populations. This will require a more
Fig. 3. Geographic distribution of 426 treating hospitals by observed/expected (O/E) ratio category and annual case volume.
Bristow. Risk-Adjusted Model for Ovarian Cancer Care. Obstet Gynecol 2020.
Table 4. Cross-Tabulation of Hospital Observed/Expected Ratio Classification and Annual Volume Criteria
O/E Ratio Category
Low Volume
(Fewer Than 20 Cases/y)
High Volume
(20 or More Cases/y) Total
Low or fewer than 5 cases/y 304 (7,068) 0 (0) 304 (7,068)
Intermediate 80 (11,919) 12 (5,452) 92 (17,371)
High 28 (4,722) 2 (890) 30 (5,612)
Total 412 (23,709) 14 (6,342) 426 (30,051)
Data are number of hospitals (number of corresponding cases).
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Table 5. Unadjusted and Adjusted Odds Ratios of Access to Centers With High Observed/Expected Ratios
Characteristic Unadjusted OR (95% CI) Adjusted ORs (95% CI)
Patient demographics
Age at diagnosis (y) 0.992 (0.990–0.994)* 0.995 (0.992–0.997)*
Year of diagnosis 1.02 (1.01–1.03)* 1.02 (1.01–1.03)*
Race
Non-Hispanic white 1.00 1.00
Non-Hispanic black 0.78 (0.68–0.91)† 0.91 (0.78–1.06)
Hispanic 0.79 (0.73–0.86)* 0.85 (0.78–0.93)*
Asian or Pacific Islander 1.33 (1.22–1.45)* 1.21 (1.11–1.33)*
Native American or unknown 0.94 (0.65–1.34) 0.91 (0.63–1.32)
Insurance
Managed care 1.00 1.00
Medicare 0.64 (0.60–0.69)* 0.74 (0.68–0.81)*
Medicaid 0.98 (0.88–1.08) 1.19 (1.07–1.33)†
Other insurance 0.76 (0.69–0.83)* 0.68 (0.62–0.75)*
Not insured 1.21 (1.03–1.41)‡ 1.41 (1.20–1.66)*
Unknown 1.16 (0.95–1.40) 1.34 (1.10–1.63)†
SES category
Highest 1.00 1.00
Higher-middle 0.80 (0.74–0.87)* 0.79 (0.73–0.86)*
Middle 0.58 (0.53–0.63)* 0.58 (0.53–0.63)*
Lower-middle 0.52 (0.47–0.57)* 0.51 (0.46–0.56)*
Lowest 0.42 (0.38–0.47)* 0.41 (0.36–0.46)*
Marital status
Single or unknown 1.00 1.00
Married 1.03 (0.98–1.10) 0.94 (0.89–1.002)
CCI score
0 1.00 1.00
1 0.87 (0.81–0.94)* 0.95 (0.88–1.02)
2 or more 0.74 (0.69–0.80)* 0.91 (0.83–0.99)‡
Unknown 1.16 (1.04–1.29)† 1.15 (1.02–1.29)‡
Tumor characteristics
Grade (differentiation)
I (well differentiated) 1.00 1.00
II (moderately well differentiated) 0.97 (0.85–1.10) 0.99 (0.87–1.13)
III (poorly differentiated) 0.99 (0.88–1.11) 0.99 (0.87–1.12)
IV (undifferentiated or anaplastic) 1.03 (0.91–1.17) 0.95 (0.82–1.09)
Grade and differentiation not stated 0.83 (0.74–0.93)† 0.93 (0.81–1.06)
Stage
I 1.00 1.00
II 1.01 (0.90–1.13) 1.03 (0.91–1.16)
III 1.06 (0.98–1.14) 1.14 (1.04–1.24)†
IV 0.85 (0.78–0.92)* 1.01 (0.92–1.12)
Size (cm)
Less than 5 1.00 1.00
5–10 1.05 (0.95–1.16) 1.05 (0.95–1.17)
More than 10 c 1.11 (1.01–1.22)‡ 1.13 (1.02–1.24)‡
Unknown 0.82 (0.75–0.90)* 0.90 (0.82–0.995)‡
Histology
Serous 1.00 1.00
Mucinous 0.91 (0.80–1.03) 0.90 (0.79–1.04)
Endometrioid 1.01 (0.91–1.11) 0.97 (0.87–1.08)
Clear cell 1.02 (0.90–1.15) 0.92 (0.81–1.06)
Adenocarcinoma, NOS 0.81 (0.73–0.90)* 1.03 (0.92–1.15)
Others 0.91 (0.84–0.98)‡ 0.95 (0.87–1.03)
OR, odds ratio; SES, socioeconomic status; CCI, Charlson Comorbidity Index; NOS, not otherwise specified.
* P,.001.
† P,.01.
‡ P,.05.
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detailed understanding of the specific barriers (eg,
financial, geographic, cultural, health literacy) affect-
ing the populations most vulnerable to disparities in
access to expert care.17,36,48
There are several limitations that must be con-
sidered when interpreting the data presented. First,
the retrospective, population-based cohort study
design is subject to the potential for selection and
reporting bias inherent to such methodology. With
respect to the California Cancer Registry specifically,
the reporting facility may not be the same facility in
which the patient receives the majority of her care,
and satellite facilities may report under their parent
institution. In addition, registry data may be subject to
underreporting of chemotherapy administration.49 As
an observational study the possibility exists that
unmeasured confounding variables could have
affected the observed results. Lastly, the current find-
ings may not be generalizable to geographic locations
outside of California.
Despite these limitations, several important con-
clusions can be drawn from the current data. First, the
larger, more expansive and detailed data set validates
our initial findings that the observed/expected ratio
model for ovarian cancer care is both a valid and
practical measure of hospital-based ovarian cancer
care quality and incorporates the three critical com-
ponents of the Donabedian paradigm for healthcare
quality, namely structure (case volume), process
(adherence to treatment guidelines), and outcomes
(survival).18,19 Second, access to high-performing hos-
pitals is currently limited, and marked disparities exist
for specific vulnerable populations in their ability to
access hospitals with high observed/expected ratios.
Finally, improving access to hospitals with high
observed/expected ratios through a performance-
based triage strategy for patients with suspected ovar-
ian cancer may be one of the most expedient means
available to directly improve outcomes and progress
toward true healthy equity in ovarian cancer care.
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